Garwood Elisabeth R, Burke Christopher J, Jazrawi Laith M, Adler Ronald S
Department of Radiology, NYU Langone Medical Center/Hospital for Joint Disease, New York, NY.
Department of Orthopaedic Surgery, NYU Langone Medical Center/Center for Musculoskeletal Care, New York, NY.
Ultrasound Q. 2018 Dec;34(4):278-284. doi: 10.1097/RUQ.0000000000000339.
Emerging musculoskeletal applications for local administration of autologous bone marrow aspirate concentrate (BMAC) include treatment of fractures, osteonecrosis, osteochondral injuries, osteoarthritis, ligament injury, tendon injury, and tendonopathies. Ultrasound-guided technique for various BMAC injection sites is detailed in this technical report and our preliminary clinical experience outlined.Five patients, 1 woman and 4 men, were treated with 6 peri/intratendinous (n = 4) or intraarticular (n = 2) BMAC injections between July 5, 2015 and December 31, 2016 for the clinical indications of common hamstrings origin tendinosis (n = 4), hip labral tear (n = 1), and osteochondral lesion of the talus (n = 1).All procedures were technically successful, with BMAC locally administered to the therapeutic target and no procedural complications observed. Clinical follow-up was available for 5 of 6 procedures. Four of 5 injections resulted in self-reported symptomatic improvement (clinical follow-up range, 2-12 months). One 72-year-old man with right common hamstrings origin tendinosis reported no improvement after BMAC injection.The technology is now available to support ultrasound-guided, autologous BMAC administration by the musculoskeletal interventionalist for common indications. Our initial clinical experience is consistent with early reports in the literature. This technique is well tolerated by symptomatic patients on an outpatient basis, and rates of self-reported symptomatic relief are high. Mechanism of action, long-term safety, and long-term clinical efficacy remain largely undefined.
自体骨髓抽吸浓缩物(BMAC)局部给药在肌肉骨骼系统中的新兴应用包括治疗骨折、骨坏死、骨软骨损伤、骨关节炎、韧带损伤、肌腱损伤和肌腱病。本技术报告详细介绍了各种BMAC注射部位的超声引导技术,并概述了我们的初步临床经验。2015年7月5日至2016年12月31日期间,对5例患者(1名女性和4名男性)进行了6次经皮/肌腱内(n = 4)或关节内(n = 2)BMAC注射,治疗常见的腘绳肌起点肌腱病(n = 4)、髋关节盂唇撕裂(n = 1)和距骨骨软骨损伤(n = 1)。所有手术在技术上均获成功,BMAC均局部注射到治疗靶点,未观察到手术并发症。6例手术中有5例获得了临床随访。5次注射中有4次自我报告症状改善(临床随访时间为2 - 12个月)。1名72岁患有右侧腘绳肌起点肌腱病的男性在BMAC注射后报告无改善。现在,该技术可支持肌肉骨骼介入医生在超声引导下对常见适应症进行自体BMAC给药。我们的初步临床经验与文献中的早期报告一致。该技术在门诊有症状的患者中耐受性良好,自我报告症状缓解的比例很高。作用机制、长期安全性和长期临床疗效在很大程度上仍不明确。